Corporate Profile

Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Upcoming Events

SEC Filings

Statement of changes in beneficial ownership of securities

4

Official notification to shareholders of matters to be brought to a vote ("Proxy")

DEF 14A

Additional proxy soliciting materials - definitive

DEFA14A